b'I N T R O D U C T I O NClonality TestsThe unique process of genetic rearrangements in the immunoglobulin (Ig) and T-cell receptor (TCR) gene loci during immune cell development and maturation generates a vast poolof genetically distinct cells. During early lymphoid differentiation, genes encoding the Ig and TCR molecules are formedby stepwise rearrangement of variable (V), diversity (D), and joining (J) gene segments.During this V-D-J recombination process, nucleotides are deleted and randomly insertedat the joining sites, resulting in an enormous diversity of unique antigen receptors. As Ig/TCR gene rearrangements occur sequentially in the earliest stages of lymphoid differentiation, they are present in almost all immature and mature lymphoid cells.Since lymphoma is a cancer of the lymphatic or the immune system, the vast majorityof lymphomas exhibit rearrangements in Ig and/or TCR genes. Lymphoid malignancies are characterized by the reduced population diversity of these gene loci originating from the proliferative transformation of an individual lymphoid cell. The associated cellular population typically shares one or more cell-specific or clonal antigen-receptor gene rearrangements. The detection of these clonal cells provides the basis for clonality assessment in leukemia, lymphoma, and hematologic disease diagnosis. Invivoscribe (LabPMMs parent company) is an industry pioneer with 25 years of experiencein providing clonality test solutions. Our expertise in clonality testing assures the highest ratesof detection of clonal populations as well as international standardization of results.LabPMM Services Catalog 2021|23'